Teleflex launches BIOMAG III trial, analyst consensus on the shares stays cautious

By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-25, 13:53.

Teleflex Inc. (US8793691069) has initiated its BIOMAG III clinical study in coronary scaffolds while the NYSE-listed medical technology group continues to carry a Hold consensus among Wall Street analysts, according to recent data and market commentary.

What the new BIOMAG III study covers

Teleflex has launched the BIOMAG III study to evaluate its resorbable coronary scaffold technology in a further clinical setting, building on earlier BIOMAG work aimed at treating coronary artery disease in a fully bioresorbable manner, as a recent specialist report notes Intellectia.ai coverage of the BIOMAG III launch.

The study focuses on a magnesium-based scaffold platform designed to provide temporary vessel support before gradually resorbing, a concept that differs from permanent metallic stents used by peers such as Abbott Laboratories in interventional cardiology.

Analyst ratings remain at Hold

Analyst data compiled by MarketBeat show that Teleflex shares currently carry a consensus rating of Hold based on 10 Wall Street recommendations, with 4 Buy, 5 Hold and 1 Sell ratings on record over the past 12 months MarketBeat analyst consensus for Teleflex.

On the same platform, the average 12?month price target stands at around 126.73 US dollars per share, underscoring a cautious stance toward the stock despite its established position in the medical instruments space.

The product behind the stock

Teleflex generates a significant portion of its revenue from interventional cardiology and vascular products, including coronary and peripheral access catheters, hemostasis devices and specialty guidewires, which are used by hospitals and cath labs worldwide in minimally invasive procedures to treat cardiovascular disease.

Where the stock trades today

The Teleflex shares (US8793691069) last traded on the NYSE on 2026-06-24 at 126.73 US dollars in regular trading, according to closing data provided by MarketBeat and US exchange disclosures MarketBeat Teleflex quote and forecast page.

Disclaimer: This article is for informational purposes only and does not constitute investment advice, investment recommendation or an offer or solicitation to buy or sell any financial instrument. Investors should conduct their own research and consider their individual financial situation before making investment decisions.